NCT06295692

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Name: Clinical Trial NCT06295692
Creator: Janssen Pharmaceutical K.K.
Keywords: Generalized Pustular Psoriasis,Erythrodermic Psoriasis, JNJ-77242113, Phase 3, drug, clinical trial, Japan

A Phase 3, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Janssen Pharmaceutical K.K.·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Generalized Pustular Psoriasis,Erythrodermic Psoriasis
Drug/Device/Intervention: JNJ-77242113
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Janssen Pharmaceutical K.K.
Location: Hokkaido,Ichinomiya,Itabashi Ku,Kitakyushu-shi,Kumamoto,Nagoya,Osaka,Sendai,Shimotsuga Gun,Shinjuku,Toyoake,Tsu, Japan

Timeline & enrollment

Phase: Phase 3
Start date: Feb 09, 2024
End date: Dec 23, 2027
Enrollment: 16 participants

Primary outcome

Percentage of Participants With Generalized Pustular Psoriasis (GPP) who Experience Treatment Success Based on Clinical Global Impression (CGI) Scale According to Japanese Dermatological Association (JDA) Total Score at Week 16,Percentage of Participants With Erythrodermic Psoriasis (EP) who Experience Treatment Success Based on CGI Scale at Week 16

Summary

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

ICD-10 classifications

Generalized pustular psoriasisPsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06295692
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06295692 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Pharmaceutical K.K. and is currently Recruiting. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.